Physician profile
Chitra Kumar
NPI 1083663496
$4,940.90
in general payments reported to CMS, 2019-2025
50 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $153 · 2021: $140 · 2022: $837 · 2023: $1,156 · 2024: $1,157 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,016 · Education: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.16 |
| Education | $552.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $553.56 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $471.20 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Daiichi Sankyo INC. | $308.47 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Amgen INC. | $268.37 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Astellas Pharma US INC | $253.96 | 2023-2024 | Xtandi |
| Astrazeneca Pharmaceuticals Lp | $226.23 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Gilead Sciences, INC. | $210.41 | 2022-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $191.47 | 2023-2025 | Libtayo |
| Eisai INC. | $180.01 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $161.69 | 2022-2025 | |
| Celgene Corporation | $160.84 | 2019-2023 | Reblozyl, Opdualag |
| Aveo Pharmaceuticals, INC. | $158.33 | 2022-2023 | Fotivda |
| Pfizer INC. | $156.44 | 2022-2025 | |
| Lilly USA, LLC | $125.69 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $120.44 | 2019-2025 | Jakafi |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $109.96 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $104.29 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.42 | 2022-2025 | Iclusig, Ninlaro |
| Seagen INC. | $85.72 | 2023-2024 | Padcev |
| Tempus Ai, INC | $62.96 | 2024-2025 | Xt Cdx |
| Exelixis INC. | $62.46 | 2023-2024 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $62.38 | 2025 | Onivyde |
| Abbvie INC. | $62.13 | 2023-2025 | |
| Glaxosmithkline, LLC. | $59.04 | 2021-2025 | Jemperli, Zejula |
| Merck Sharp & Dohme LLC | $55.81 | 2019-2022 | |
| Adaptive Biotechnologies Corporation | $50.52 | 2023 | Clonoseq |
| Puma Biotechnology, INC. | $49.53 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $48.86 | 2022-2025 | Monoferric |
| Geron Corporation | $48.12 | 2025 | Rytelo |
| Taiho Oncology, INC. | $38.11 | 2024-2025 | |
| Octapharma USA, INC. | $33.76 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Beone Medicines USA, INC. | $32.19 | 2025 | Brukinsa |
| Genentech USA, INC. | $31.46 | 2022-2025 | Venclexta |
| Emd Serono, INC. | $31.39 | 2023-2024 | Bavencio |
| Acrotech Biopharma INC. | $30.31 | 2024 | Ryzneuta |
| Coherus Oncology, INC. | $26.87 | 2022-2023 | |
| Dendreon Pharmaceuticals LLC | $19.07 | 2024 | Provenge |
| Invivyd INC | $18.68 | 2025 | Pemgarda |
| Blueprint Medicines Corporation | $18.31 | 2024 | Ayvakit |
| Sobi, INC | $17.76 | 2025 | |
| Apellis Pharmaceuticals, INC. | $16.57 | 2023 | Empaveli |
| Servier Pharmaceuticals LLC | $16.37 | 2024 | |
| Foundation Medicine, INC. | $15.83 | 2020 | |
| Genzyme Corporation | $15.60 | 2021 | |
| Sumitomo Pharma America, INC. | $14.65 | 2025 | Orgovyx |
| Heron Therapeutics, INC. | $14.20 | 2022 | |
| Rigel Pharmaceuticals, INC. | $13.90 | 2022 | |
| Beigene USA, INC. | $13.26 | 2022 | |
| Karyopharm Therapeutics INC. | $12.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chitra Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.